2022 was one of the most consequential in recent European history, witness to a series of overlapping crises: the aftermath of the COVID-19 pandemic, Russia’s invasion of Ukraine, fast-growing population displacements, the MPOX outbreak, shrinking civil society spaces and the deepening of socioeconomic inequalities, among others.
Within this context, C-EHRN’s monitoring activities have been embedded with increased urgency. Whilst the effects of these developments have been felt in nearly everyone’s life, people who use drugs, as well as other marginalised and underserved communities, have particularly and disproportionately experienced its negative consequences. Equally, harm reduction organizations in Europe have been put to the test.
In combination with advocacy, the application of civil society-led monitoring tools is crucial to hold governments accountable and to improve the care and support that people who use drugs receive and their environments.
Together with more than one hundred organizations and individuals from thirty-four European countries, C-EHRN set up for itself the task to provide an in-depth look at Harm Reduction in Europe. To this end, the annual 2022 Data Report focused on three main themes: harm reduction essential services, Hepatitis C, and new drug trends. In addition to the data collected, this year C-EHRN conducted in-depth interviews with all its Focal Points, allowing for a richer picture of the developments from last year.
C-EHRN is proud and grateful to present its 2023 Network Report, providing a summarised version of the activities undertaken last year. In this document, we are looking back at a year full of tasks, challenges and opportunities.
Multiple authors 
As part of our 2022 work plan, C-EHRN is working with different Expert Groups and will organize consultations addressing a variety of topics. With this open call, C-EHRN would like to invite all its members and partners to engage and participate in these Expert Groups and Consultations based on their interest and expertise in any […]
